Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313637 | 0.77 | HRH2 (0.34) | — | |
| Adenine SCHEMBL23070888 | 0.76 | ADORA2A (0.38) | HIF1A | |
| SCHEMBL11903082 | 0.76 | CYP3A4 (0.34) | HIF1A | |
| SCHEMBL15597610 | 0.76 | CSNK2A2 (0.32) | — | |
| SCHEMBL129625 | 0.76 | HTT (0.34) | HIF1A | |
| SCHEMBL10435357 | 0.75 | CDK1 (0.31) | — | |
| SCHEMBL5019516 | 0.73 | PRKACA (0.38) | — | |
| SCHEMBL11461668 | 0.72 | SMN1; SMN2 (0.46) | HIF1A | |
| Adenine SCHEMBL5821345 | 0.72 | ADORA2A (0.38) | HIF1A | |
| SCHEMBL6270505 | 0.72 | CDK1 (0.47) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659015-A | Synthesis method for promoting 6-alkyl purine nucleoside by using water system illumination | 新乡学院 | 2024-03-08 | — | — | CN | claimed |
| EP-2322518-B1 | Method of manufacture of 1,3-dioxolane and 1,3-oxathiolane nucleosides | GILEAD SCIENCES INC (US) | 2015-02-25 | — | — | EP | claimed |
| US-20140121186-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2014-05-01 | — | — | US | claimed |
| WO-2011011519-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OCULAR CONDITIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | claimed |
| US-6939965-B2 | Process of manufacture of 1,3-oxathiolane nucleosides using titanium trichloride mono-isopropoxide | GILEAD SCIENCES, INC. (US) | 2005-09-06 | — | — | US | claimed |
| US-6518425-B1 | A process for producing a 1,3-oxathiolane nucleoside comprising reacting a 5-halo-2-protected-oxymethyl-1,3-oxathiolane with a silylated purine or pyrimidine without the addition of a Lewis acid or an additional base to the reaction | EMORY UNIVERSITY | 2003-02-11 | — | — | US | claimed |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | APOTEX PHARMACHEM INC (CA) | 2003-01-16 | — | — | US | claimed |
| WO-2021226584-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES BY ADP-RIBOSYL CYCLASES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-2697242-B1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-2696681-B1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20170333459-A1 | METHODS OF TREATING ORTHOPOX VIRUS INFECTIONS AND ASSOCIATED DISEASES | CHIMERIX, INC. | 2017-11-23 | — | — | US | disclosed |
| EP-2696679-B1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2012799-B1 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX INC (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2000009531-A2 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009494-A1 | METHOD OF MANUFACTURE OF 1,3-OXATHIOLANE NUCLEOSIDES | TRIANGLE PHARMACEUTICALS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| US-5869467-A | VIRICIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1999-02-09 | — | — | US | disclosed |
| US-5641763-A | N-phosphonylmethoxyalkyl derivatives of pyrimdine and purine bases and a therapeutical composition therefrom with antiviral activity | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-06-24 | — | — | US | disclosed |
| US-5142051-A | Viricides special for mutants of herpes viruses | CESKOSLOVENSKA AKADEMIE VED (CS) | 1992-08-25 | — | — | US | disclosed |
| EP-0253412-B1 | N-PHOSPHONYLMETHOXYALKYL DERIVATIVES OF PYRIMIDINE AND PURINE BASES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFROM WITH ANTIVIRAL ACTIVITY | Ceskoslovenska akademie ved (CS) | 1990-10-31 | — | — | EP | disclosed |
| EP-0253412-A2 | N-Phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity | Ceskoslovenska akademie ved (CS) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121186-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | EYA3, EYA2, PDE6C | HIF1A 685/4885 |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | SLC29A1, NUDT1, SLC28A1 | HIF1A 3969/4885 |
| US-20170333459-A1 | METHODS OF TREATING ORTHOPOX VIRUS INFECTIONS AND ASSOCIATED DISEASES | OAT, PNPO, OTC | HIF1A 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.